Stephen D Mikolajczyk

USPTO Granted Patents = 15 (Patent Applications = 4)

CIPO Patents = 2

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.1

ph-index = 5

Forward Citations = 75(Granted Patents)

Company Filing History:

Hybritech Incorporated

patents

1 out of 590

Beckman Coulter, Inc.

patents

4. 1 out of 1,742

Mayo Foundation for Medical Education and Research

patents

5. 1 out of 1

Hyrbritech Incorporated

patent

6. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2023

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11719692 - Devices and methods of cell capture and analysis (2023-08-08),

2. 10527611 - Devices and methods of cell capture and analysis (2020-01-07),

3. 9671407 - Devices and methods of cell capture and analysis (2017-06-06),

4. 9347946 - Methods and reagents for signal amplification (2016-05-24),

5. 9128082 - Devices and methods of cell capture and analysis (2015-09-08),

6. 9040255 - Use of diazolidinyl urea for anti-clumping of biological samples (2015-05-26),

7. 7659073 - Forms of prostate specific antigens and methods for their detection (2010-02-09),

8. 7288636 - Forms of prostate specific antigens and methods for their detection (2007-10-30),

9. 7211397 - Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection (2007-05-01),

10. 6482599 - Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such (2002-11-19),

11. 6472143 - Complex of human kallikrein 2 (hK2) and protease inhibitor-6 (PI-6) in prostate tumor tissue and methods of using the complex and its constituents (2002-10-29),

12. 6423503 - Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone (2002-07-23),

13. 6284873 - Complex of human kallikrein 2 (hK2) and protease inhibitor-6 (PI-6) in prostate tumor tissue and methods of using the complex (2001-09-04),

14. 6103237 - Stable variant hK2 polypeptide (2000-08-15),

15. 6093796 - Recombinant hK2 polypeptide (2000-07-25),

Title: The Innovative Contributions of Stephen D. Mikolajczyk

Introduction

Stephen D. Mikolajczyk is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the area of cell capture and analysis. With a total of 15 patents to his name, Mikolajczyk's work has the potential to impact medical diagnostics and treatment.

Latest Patents

One of his latest patents focuses on devices and methods for cell capture and analysis. This invention provides a device designed to isolate target biomolecules or cells from biological samples. The device includes a loading mixture containing the biological sample and a first binding entity that specifically binds to the target biomolecule or target cell. Additionally, it features a micro-channel coated with a second binding entity that binds directly or indirectly to the first binding entity. The methods disclosed in this patent aim to capture, detect, and evaluate target biomolecules or target cells, such as cancer cells, in biological samples.

Career Highlights

Throughout his career, Stephen D. Mikolajczyk has worked with notable companies in the biotechnology sector, including Biocept, Inc. and Hybritech Incorporated. His experience in these organizations has contributed to his expertise in developing innovative solutions for cell analysis.

Collaborations

Mikolajczyk has collaborated with several professionals in his field, including Pavel Tsinberg and Harry G. Rittenhouse. These collaborations have likely enhanced his research and development efforts.

Conclusion

Stephen D. Mikolajczyk's innovative work in cell capture and analysis exemplifies the impact of biotechnology on healthcare. His numerous patents and collaborations highlight his commitment to advancing medical technology.

This text is generated by artificial intelligence and may not be accurate.